Shire has called time on its $50 billion acquisition spree as it attempts to digest its biggest deal yet.
The FTSE 100 pharmaceuticals group expects its $32 billion (£22 billion) acquisition of Baxalta to close this year and said that it would concentrate on integrating the American business before embarking on any other deals.
Flemming Ornskov, the chief executive, said that the company had “more than enough to focus on” after the Baxalta deal and the $6 billion purchase of Dyax announced in November and the $5.2 billion purchase of NPS earlier last year.
Mr Ornskov said that the Baxalta deal would transform Shire into the world’s largest rare-disease specialist.
“The integration is progressing very well, and we are on track for a mid-this-year close,”